PARIS--(BUSINESS WIRE)--Regulatory News:

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that oral presentations on LUMEVOQ and GS030 will be featured at the 2021 ASRS and ESGCT meetings in October. Senior management will also attend and present at several investor and industry conferences in the same month.

Chardan 5th Annual Genetic Medicines ConferenceOctober 4-5, 2021 VirtualBernard Gilly, Co-founder & Chief Executive Officer, will present on Monday October 4, 2021, at 8.00 am ET and the management team will host investor meetings during the conference.

A webcast of the fireside chat will be available at https://bit.ly/3zZOGsM for 90 days.

HealthTech Innovation Days (HTID)October 4-5, 2021 VirtualGenSight Biologics management team will host investor meetings during the conference.

2021 Advanced Therapies Congress LIVEOctober 5-6, 2021 ExCel, London (United Kingdom)Magali Taiel, MD, Chief Medical Officer, will present LUMEVOQ on Wednesday October 6, 2021, at 1.30 pm GMT.

2021 OIS @ ASRSOctober 7, 2021 San Antonio, Texas (United States) & VirtualMagali Taiel, MD, Chief Medical Officer, will present on Thursday October 7, 2021, at 9.09 am CDT.

39th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS)October 8-12, 2021 San Antonio, Texas (United States)

Optogenetics in the Clinic: Safety and Efficacy Updates on the Phase I/II Clinical Trial PIONEER will be presented by Joseph Martel, MD, University of Pittsburgh School of Medicine, United States and Investigator in the PIONEER trial.

2021 ARM Cell & Gene Meeting on the MesaOctober 12-14, 2021 Carlsbad, California (United States) & VirtualMagali Taiel, MD, Chief Medical Officer, pre-recorded a Company presentation that will be available during the conference.

28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)October 19-22, 2021 Virtual

The phase III REFLECT trial: Efficacy and safety of bilateral gene therapy for Leber Hereditary Optic Neuropathy (LHON) will be presented by Patrick Yu Wai Man, MD, University of Cambridge, United Kingdom and Investigator in the REFLECT trial.

Partial recovery of visual function in a blind patient after optogenetic therapy for non-syndromic Retinitis Pigmentosa will be presented by Jos-Alain Sahel, MD, University of Pittsburgh School of Medicine, United States and Co-founder of GenSight Biologics.

BIO-Europe 2021October 25-28, 2021 VirtualGenSight Biologics management team will host partnering meetings during the conference.

GenSight Biologics management team will also present at the following conferences:

Mitochondrial Diseases Conference 2021 by Mitocon // October 15-16, virtualAdvancing Gene Therapy 2021 // October 18-20, Boston, USA & virtual

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics lead product candidate, LUMEVOQ (GS010; lenadogene nolparvovec), has been submitted for marketing approval in Europe for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

Go here to see the original:
Clinical Data on GenSight Biologics' LUMEVOQ and GS030 Gene Therapies to be Presented at 2021 ASRS, ESGCT and Several Investor and Industry Meetings...